AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28178145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency high-intensity interval training (LfHIIT)
Number of subjects: 33
Study 28178145 — intervention group
Group type: COMPARATOR
Intervention: Control (inactive)
Number of subjects: 33
Study 25966339 — intervention group
Group type: EXPERIMENTAL
Intervention: cART initiated one week after TB therapy
Number of subjects: 478
Study 25966339 — intervention group
Group type: EXPERIMENTAL
Intervention: cART initiated four weeks after TB therapy
Number of subjects: 478
Study 25966339 — intervention group
Group type: EXPERIMENTAL
Intervention: cART initiated eight weeks after TB therapy
Number of subjects: 478
Study 23089653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral mucoadhesive tablet of amitriptyline
Number of subjects: 25
Study 23089653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 22358273 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP® group (BG) with conventional respiratory therapy and BiPAP® for 30 minutes twice a day
Number of subjects: 26
Study 22358273 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) with conventional respiratory therapy only
Number of subjects: 26
Study 22358273 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CG and BG)
Number of subjects: 26
Study 19231641 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% lidocaine with 1:100,000 epinephrine
Number of subjects: 149
Study 19231641 — intervention group
Group type: COMPARATOR
Intervention: 0.5% lidocaine with 1:200,000 epinephrine
Number of subjects: 149
Study 16490021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex therapy
Number of subjects: 24
Study 16490021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16490021 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingko biloba
Number of subjects: 24
Study 12708976 — intervention group
Group type: EXPERIMENTAL
Intervention: DB PCFC with metabisulfite‐free seasoning (up to 1340 mg)
Number of subjects: 30
Study 12708976 — intervention group
Group type: EXPERIMENTAL
Intervention: Prick tests with allergenic extract
Number of subjects: 30
Study 12708976 — intervention group
Group type: EXPERIMENTAL
Intervention: Prick tests with B. nigra ground seeds
Number of subjects: 30
Study 12708976 — intervention group
Group type: EXPERIMENTAL
Intervention: Prick tests with B. juncea flour
Number of subjects: 30
Study 12708976 — intervention group
Group type: EXPERIMENTAL
Intervention: Prick tests with metabisulfite‐free mustard seasoning
Number of subjects: 30
Study 12708976 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE values in mustard allergy subgroup
Number of subjects: 30
Study 10743796 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFbp dimer (30 microg/kg)
Number of subjects: 33
Study 10743796 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFbp dimer (100 microg/kg)
Number of subjects: 33
Study 10743796 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFbp dimer (300 microg/kg)
Number of subjects: 33
Study 10743796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 8811328 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate meal (sugar pie)
Number of subjects: 0
Study 8811328 — intervention group
Group type: EXPERIMENTAL
Intervention: High lipid meal (whipped cream)
Number of subjects: 0
Study 8811328 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein meal (beef steak or fish fillet)
Number of subjects: 0
Study 8811328 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein meal (beef or fish)
Number of subjects: 0
Study 1547673 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting zinc insulin (Ultratard HM) before the evening meal
Number of subjects: 10
Study 1547673 — intervention group
Group type: COMPARATOR
Intervention: Intermediate isophane insulin (Protaphane HM) before the evening meal
Number of subjects: 10
Study 3908643 — intervention group
Group type: EXPERIMENTAL
Intervention: Interproximal root planing augmented by papilla reflection and fiber optic illumination (Group I)
Number of subjects: 4
Study 3908643 — intervention group
Group type: EXPERIMENTAL
Intervention: Interproximal root planing with papilla reflection only (Group II)
Number of subjects: 4
Study 3908643 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (Group III)
Number of subjects: 4
Study 30587728 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) 40 mg daily
Number of subjects: 69
Study 30587728 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (ANA) 1 mg daily
Number of subjects: 69
Study 26905871 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐EOB‐DTPA‐MRI
Number of subjects: 354
Study 26905871 — intervention group
Group type: COMPARATOR
Intervention: ECCM‐MRI
Number of subjects: 354
Study 26905871 — intervention group
Group type: COMPARATOR
Intervention: CE‐MDCT
Number of subjects: 354
Study 25243534 — intervention group
Group type: COMPARATOR
Intervention: +CS
Number of subjects: 197
Study 25243534 — intervention group
Group type: COMPARATOR
Intervention: -CS
Number of subjects: 197
Study 22311837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretraining session with low-fidelity training models
Number of subjects: 14
Study 22311837 — intervention group
Group type: COMPARATOR
Intervention: No pretraining
Number of subjects: 14
Study 20487119 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE plus fluoroscopy
Number of subjects: 43
Study 20487119 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy alone
Number of subjects: 43
Study 17485593 — intervention group
Group type: EXPERIMENTAL
Intervention: Very late stent thrombosis patients
Number of subjects: 157
Study 16207824 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) measured at baseline
Number of subjects: 840
Study 11886769 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day transdermal sequential estradiol/levonorgestrel patch (Fem7 Combi; 50 microg estradiol/10 microg levonorgestrel per 24 h)
Number of subjects: 0
Study 11886769 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study 12516795 — intervention group
Group type: EXPERIMENTAL
Intervention: Head movement during pointing task
Number of subjects: 26
Study 12516795 — intervention group
Group type: COMPARATOR
Intervention: No head movement during pointing task
Number of subjects: 26
Study 9572224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening during pregnancy
Number of subjects: 3265
Study 9572224 — intervention group
Group type: COMPARATOR
Intervention: Nonscreening (control) group
Number of subjects: 3265
Study 9572224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-exposed children
Number of subjects: 3265
Study 9572224 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-unexposed children (control)
Number of subjects: 3265
Study 7999858 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at a dosage of 28-30 IU/m2/week for at least 12 months
Number of subjects: 31
Study 7999858 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH)
Number of subjects: 31
Study 3045717 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for three days
Number of subjects: 100
Study 3045717 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim 300 mg once daily for three days
Number of subjects: 100
Study 3045717 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 100
Study 3045717 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim
Number of subjects: 100
Study 31129907 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA-intensive regimen
Number of subjects: 0
Study 31129907 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-intensive regimen
Number of subjects: 0
Study 31129907 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CEA+CT regimen
Number of subjects: 0
Study 31129907 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum surveillance regimen
Number of subjects: 0
Study 31129907 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 0
Study 27843040 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg by mouth daily starting postoperative day 1 for 15 days
Number of subjects: 3914
Study 26476515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pack free septoplasty
Number of subjects: 49
Study 23448618 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent/detergent plasma (S/D Plasma)
Number of subjects: 63
Study 23448618 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 63
Study 21203797 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 9
Study 21203797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 18458326 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of recombinant human leptin and the amylin analog pramlintide
Number of subjects: 0
Study 16799034 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol 0.5%
Number of subjects: 27
Study 16799034 — intervention group
Group type: EXPERIMENTAL
Intervention: brimonidine 0.2%
Number of subjects: 27
Study 16799034 — intervention group
Group type: EXPERIMENTAL
Intervention: dorzolamide 2%
Number of subjects: 27
Study 16799034 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 27
Study 12686331 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated troponin elevation (without CK-MB elevation)
Number of subjects: 0
Study 12686331 — intervention group
Group type: COMPARATOR
Intervention: Isolated CK-MB elevation
Number of subjects: 0
Study 12686331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both troponin and CK-MB positive
Number of subjects: 0
Study 12686331 — intervention group
Group type: COMPARATOR
Intervention: Both markers negative
Number of subjects: 0
Study 10807440 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous atrial dynamic overdrive pacing for 24 hours
Number of subjects: 96
Study 10807440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atrial pacing)
Number of subjects: 96
Study 8826488 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine patches applied for 12 hours in two of four sessions
Number of subjects: 35
Study 8826488 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine patches
Number of subjects: 35
Study 8826488 — intervention group
Group type: COMPARATOR
Intervention: Vehicle patches applied for 12 hours in one session
Number of subjects: 35
Study 8826488 — intervention group
Group type: COMPARATOR
Intervention: No-treatment observation session
Number of subjects: 35
Study 1425656 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-MST
Number of subjects: 12
Study 1425656 — intervention group
Group type: COMPARATOR
Intervention: Continuous running track test (T1)
Number of subjects: 12
Study 31174576 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliglustat
Number of subjects: 393
Study 30382274 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dose of 8 g of dried grape pomace
Number of subjects: 50
Study 30382274 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 27178738 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600mg
Number of subjects: 76
Study 27178738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 25006110 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured session/handout specific to their primary care provider (PCP)
Number of subjects: 332
Study 22525652 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine ingestion (0.3 g/kg/die for 5 consecutive days)
Number of subjects: 30
Study 22525652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20950385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 17699010 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 10613
Study 16275530 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power contrast echocardiography (CE)
Number of subjects: 36
Study 16275530 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced harmonic echocardiography (HE)
Number of subjects: 36
Study 12377150 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine consumption in high users
Number of subjects: 0
Study 12377150 — intervention group
Group type: COMPARATOR
Intervention: Caffeine consumption in low users
Number of subjects: 0
Study 12377150 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine consumption
Number of subjects: 0
Study 9927124 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic or open Nissen fundoplication (in 1 case Toupet 180 degrees posterior hemifundoplication)
Number of subjects: 20
Study 9927124 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study 7677387 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.1 mg
Number of subjects: 9
Study 7677387 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.1 mg
Number of subjects: 9
Study 7677387 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine
Number of subjects: 9
Study 7677387 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 9
Study 7677387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2196934 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg orally at the time of IUCD insertion
Number of subjects: 1813
Study 6794406 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole
Number of subjects: 52
Study 6794406 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 31116313 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 60
Study 28466803 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTAS 2 intra-rater reliability in dichotomy
Number of subjects: 47
Study 28466803 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTAS 2 intra-rater reliability in grading
Number of subjects: 47
Study 28466803 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTAS 2 intra-rater reliability for damage evaluations
Number of subjects: 47
Study 28466803 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTAS 2 inter-rater reliability at T1 in dichotomy
Number of subjects: 47
Study 28466803 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTAS 2 inter-rater reliability at T1 in grading
Number of subjects: 47
Study 28466803 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTAS 2 inter-rater reliability at T2 in dichotomy
Number of subjects: 47
Study 28466803 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTAS 2 inter-rater reliability at T2 in grading
Number of subjects: 47
Study 28466803 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTAS 2 inter-rater reliability for damage evaluation at T1
Number of subjects: 47
Study 28466803 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTAS 2 inter-rater reliability for damage evaluation at T2
Number of subjects: 47
Study 27307996 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tool for patients with CKD
Number of subjects: 264
Study 24915210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mupirocin ointment applied twice daily for 5 days before surgery
Number of subjects: 1697
Study 24915210 — intervention group
Group type: COMPARATOR
Intervention: Nasal povidone-iodine solution applied twice into each nostril within 2 hours of surgical incision
Number of subjects: 1697
Study 22561227 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative landmarks for subclavian vein cannulation
Number of subjects: 0
Study 22561227 — intervention group
Group type: COMPARATOR
Intervention: Traditional method for subclavian vein cannulation
Number of subjects: 0
Study 19996720 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 124
Study 19996720 — intervention group
Group type: COMPARATOR
Intervention: Standard Clinical Case Management
Number of subjects: 124
Study 17365095 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological representation tasks
Number of subjects: 26
Study 15119889 — intervention group
Group type: EXPERIMENTAL
Intervention: Emdogain enamel matrix proteins
Number of subjects: 8
Study 15119889 — intervention group
Group type: COMPARATOR
Intervention: Surgical debridement alone (Control)
Number of subjects: 8
Study 11477342 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/day)
Number of subjects: 141
Study 11477342 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (dose adjusted for renal function)
Number of subjects: 141
Study 11477342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 9667249 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) infused over 72 hours at an initial dose rate of 40 microg/m2/h every 3 weeks with dose adjustments based on toxicity.
Number of subjects: 45
Study 9667249 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte-colony stimulating factor (G-CSF) administered to the subsequent 29 patients on all cycles.
Number of subjects: 45
Study 9667249 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC)
Number of subjects: 45
Study 8092339 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone, 50 mg p.o.
Number of subjects: 19
Study 8092339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3289507 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ppm NO2 gas for 1 hr
Number of subjects: 18
Study 3289507 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 18
Study 29300098 — intervention group
Group type: EXPERIMENTAL
Intervention: Online workplace mental health intervention
Number of subjects: 196
Study 29300098 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 196
Study 28281235 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratafix™ 2/0‐Ethicon (S-group)
Number of subjects: 200
Study 28281235 — intervention group
Group type: COMPARATOR
Intervention: Vicryl® 2/0‐Ethicon (V-group)
Number of subjects: 200
Study 25947167 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) - 10 sessions, 30 minutes each, 2-10 Hz, intensity by tolerance, twice per week
Number of subjects: 34
Study 25947167 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 34
Study 23357545 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids (EAA) 6.7 g
Number of subjects: 15
Study 23357545 — intervention group
Group type: COMPARATOR
Intervention: Total amino acids as present in whey (Control)
Number of subjects: 15
Study 23357545 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids (EAA)
Number of subjects: 15
Study 21258926 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral minimally invasive approach (ALMI, n=20)
Number of subjects: 39
Study 21258926 — intervention group
Group type: COMPARATOR
Intervention: Modified direct-lateral approach (mDL, n=19)
Number of subjects: 39
Study 21258926 — intervention group
Group type: COMPARATOR
Intervention: Standard access (control for overweight group)
Number of subjects: 39
Study 21258926 — intervention group
Group type: COMPARATOR
Intervention: Standard access (control for older patient group)
Number of subjects: 39
Study 19764169 — intervention group
Group type: EXPERIMENTAL
Intervention: MLS‐MLR paradigm
Number of subjects: 10
Study 19764169 — intervention group
Group type: COMPARATOR
Intervention: Conventional MLR paradigm
Number of subjects: 10
Study 17806038 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-hole nipple units
Number of subjects: 20
Study 17806038 — intervention group
Group type: COMPARATOR
Intervention: Cross-cut nipple units
Number of subjects: 20
Study 15448117 — intervention group
Group type: COMPARATOR
Intervention: Insertion of microdialysis catheters
Number of subjects: 6
Study 15448117 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive low‐force exercise
Number of subjects: 6
Study 15448117 — intervention group
Group type: COMPARATOR
Intervention: Control study (rest)
Number of subjects: 6
Study 12061999 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment including lipid lowering drugs (52%), beta-blockers (50%), antiplatelet drugs (87%), ACE inhibitors (32%), nitrates (52%), calcium antagonists (31%), oral anticoagulants (8%)
Number of subjects: 618
Study 12061999 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients hospitalized during follow-up
Number of subjects: 618
Study 9691642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical application of 0.5 mg dinoprostone gel
Number of subjects: 85
Study 8591941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg single dose
Number of subjects: 117
Study 8591941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 2746645 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical intention
Number of subjects: 0
Study 2746645 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional cognitive strategies
Number of subjects: 0
Study 2746645 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional sets supporting preferred coping style
Number of subjects: 0
Study 2746645 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 195328 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I: 3 months of INH + RMP (2/7) in hospital, followed by 6 months of INH + SM (2/7) or INH + EMB (2/7) in ambulatory treatment.
Number of subjects: 276
Study 195328 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen II: 3 months of INH + SM + EMB (2/7) in hospital, followed by 6 months of INH + SM (2/7) or INH + EMB (2/7) in ambulatory treatment.
Number of subjects: 276
Study 195328 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I
Number of subjects: 276
Study 195328 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen II
Number of subjects: 276
Study 195328 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 276
Study 31691018 — intervention group
Group type: EXPERIMENTAL
Intervention: p-synephrine (3 mg kg-1)
Number of subjects: 14
Study 31691018 — intervention group
Group type: COMPARATOR
Intervention: placebo (cellulose)
Number of subjects: 14
Study 31096476 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid disease group (both hyperthyroidism and hypothyroidism)
Number of subjects: 0